by Peter Ciszewski | Sep 28, 2017
Douglas Paul, PharmD, PhD discusses some of the misconceptions around the Orphan Drug Act and how these myths are doing a great disservice to the Rare Disease Industry, specifically the pharma and biotech companies who are not getting the proper credit for the many...
by Peter Ciszewski | Sep 27, 2017
Cedars-Sinai neuroscience investigators have found that Alzheimer’s disease affects the retina — the back of the eye — similarly to the way it affects the brain. The study also revealed that an investigational, noninvasive eye scan could detect the key signs of...
by Peter Ciszewski | Sep 27, 2017
In an article Modern Medicine, (Novel Therapies Could Stem Burden of Diabetic Eye Disease) and based on a presentation given by Dr. Garweg at the 2017 Retina World Congress, the author suggests that a better understanding of the pathophysiologic mechanisms of diabetes...
by Peter Ciszewski | Sep 26, 2017
Treatments for childhood cancer are often intense and carry the risk of lifelong health problems for survivors. An analysis of 23,600 childhood cancer survivors in the Childhood Cancer Survivor Study (CCSS), funded by the National Institutes of Health, found that the...
by Peter Ciszewski | Sep 26, 2017
Scientists may have developed the first targeted, oral, tumor-type agnostic therapy – a cancer medicine that works comparably well across many kinds of cancer, regardless of patient age. In clinical trials of adults and children with 17 different types of advanced...
